全文获取类型
收费全文 | 8886篇 |
免费 | 416篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 171篇 |
妇产科学 | 65篇 |
基础医学 | 1054篇 |
口腔科学 | 211篇 |
临床医学 | 566篇 |
内科学 | 2633篇 |
皮肤病学 | 116篇 |
神经病学 | 524篇 |
特种医学 | 320篇 |
外科学 | 1522篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 142篇 |
眼科学 | 121篇 |
药学 | 483篇 |
中国医学 | 12篇 |
肿瘤学 | 1306篇 |
出版年
2024年 | 9篇 |
2023年 | 78篇 |
2022年 | 192篇 |
2021年 | 300篇 |
2020年 | 150篇 |
2019年 | 201篇 |
2018年 | 227篇 |
2017年 | 188篇 |
2016年 | 239篇 |
2015年 | 229篇 |
2014年 | 293篇 |
2013年 | 363篇 |
2012年 | 655篇 |
2011年 | 715篇 |
2010年 | 425篇 |
2009年 | 337篇 |
2008年 | 569篇 |
2007年 | 597篇 |
2006年 | 594篇 |
2005年 | 559篇 |
2004年 | 527篇 |
2003年 | 509篇 |
2002年 | 501篇 |
2001年 | 71篇 |
2000年 | 72篇 |
1999年 | 78篇 |
1998年 | 99篇 |
1997年 | 72篇 |
1996年 | 40篇 |
1995年 | 58篇 |
1994年 | 48篇 |
1993年 | 46篇 |
1992年 | 36篇 |
1991年 | 45篇 |
1990年 | 27篇 |
1989年 | 25篇 |
1988年 | 24篇 |
1987年 | 10篇 |
1986年 | 19篇 |
1985年 | 17篇 |
1984年 | 18篇 |
1983年 | 10篇 |
1982年 | 14篇 |
1981年 | 10篇 |
1980年 | 8篇 |
1979年 | 12篇 |
1978年 | 7篇 |
1977年 | 14篇 |
1976年 | 5篇 |
1969年 | 4篇 |
排序方式: 共有9367条查询结果,搜索用时 15 毫秒
991.
Thierry Andre Mayur Amonkar Josephine M Norquist Kai-Keen Shiu Tae Won Kim Benny Vittrup Jensen Lars Henrik Jensen Cornelis J A Punt Denis Smith Rocio Garcia-Carbonero Isabel Sevilla Christelle De La Fouchardiere Fernando Rivera Elena Elez Luis A Diaz Takayuki Yoshino Eric Van Cutsem Ping Yang Dung T Le 《The lancet oncology》2021,22(5):665-677
992.
Masuda Norikazu Bando Hiroko Yamanaka Takashi Kadoya Takayuki Takahashi Masato Nagai Shigenori E. Ohtani Shoichiro Aruga Tomoyuki Suzuki Eiji Kikawa Yuichiro Yasojima Hiroyuki Kasai Hiroi Ishiguro Hiroshi Kawabata Hidetaka Morita Satoshi Haga Hironori Kataoka Tatsuki R. Uozumi Ryuji Ohno Shinji Toi Masakazu 《Breast cancer research and treatment》2021,188(1):117-131
Breast Cancer Research and Treatment - To investigate clinical usefulness of eribulin-based neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Patients in group A... 相似文献
993.
Sueoka Satoshi Sasada Shinsuke Masumoto Norio Emi Akiko Kadoya Takayuki Okada Morihito 《Breast cancer research and treatment》2021,187(1):125-133
Breast Cancer Research and Treatment - This study compares the sensitivity of dedicated breast positron emission tomography (DbPET) and whole body positron emission tomography (WBPET) in detecting... 相似文献
994.
Kato Ryoji Hayashi Hidetoshi Sakai Kazuko Suzuki Shinichiro Haratani Koji Takahama Takayuki Tanizaki Junko Nonagase Yoshikane Tanaka Kaoru Yoshida Takeshi Takeda Masayuki Yonesaka Kimio Kaneda Hiroyasu Nishio Kazuto Nakagawa Kazuhiko 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(9):1628-1639
International Journal of Clinical Oncology - We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance... 相似文献
995.
Takuma Saito Tomohide Tsukahara Takeshi Suzuki Iyori Nojima Hiroki Tadano Noriko Kawai Terufumi Kubo Yoshihiko Hirohashi Takayuki Kanaseki Toshihiko Torigoe Liming Li 《Cancer science》2021,112(2):550-562
Photodynamic therapy (PDT) using the photosensitizer talaporfin sodium (talaporfin) is a new mode of treatment for cancer. However, the metabolic mechanism of talaporfin has not been clarified. Thus, we investigated the uptake, transportation, and elimination mechanisms of talaporfin in carcinoma and sarcoma. The results showed that talaporfin co‐localized in early endosomes and lysosomes. Talaporfin uptake was via clathrin‐ and caveolae‐dependent endocytosis and a high amount of intracellular ATP was essential. Inhibition of lysosomal enzymes maintained intracellular talaporfin levels. Inhibition of K‐Ras signaling reduced talaporfin uptake in carcinoma and sarcoma cell lines. Talaporfin was taken up by clathrin‐ and caveolae‐dependent endocytosis, translocated from early endosomes to lysosomes, and finally degraded by lysosomes. We also demonstrated that ATP is essential for the uptake of talaporfin and that activation of K‐Ras is involved as a regulatory mechanism. These results provide new insights into the metabolism of talaporfin in cancer cells for the enhancement of PDT for carcinoma and sarcoma. 相似文献
996.
Sohei Kobayashi Takaki Hiwasa Takayuki Ishige Masayuki Kano Tyuji Hoshino Bahityar Rahmutulla Masanori Seimiya Hideaki Shimada Fumio Nomura Hisahiro Matsubara Kazuyuki Matsushita 《Cancer science》2021,112(2):847-858
There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐lacking exon2 (FIRΔexon2), anti‐sorting nexin 15, and anti‐spermatogenesis and oogenesis–specific basic helix–loop–helix 1 were markedly higher in GC patients than in healthy donors (HDs). These Abs were identified by large‐scale serological identification of antigens by recombinant cDNA expression cloning screenings and their expression levels were evaluated by amplified luminescence proximity homogeneous assay. In particular, compared with age‐matched HDs, the level of anti‐FIRΔexon2 Abs in GC patients was significantly higher (P < .001). The Spearman''s rank correlation analysis between anti‐FIRΔexon2 Abs and clinically available tumor markers such as carcinoembryonic antigen (CEA) was statistically insignificant, indicating that FIRΔexon2 Abs is an independent biomarker. We performed receiver‐operating curve analysis to evaluate the anti‐FIRΔexon2 Ab as a candidate biomarker with CEA and carbohydrate antigen 19‐9 (CA19‐9). The overall survival of GC patients with high anti‐FIRΔexon2 Abs titer was significantly favorable (P = .04) than that of GC patients who were below detection level of anti‐FIRΔexon2 Abs. However, clinical stages were not apparently correlated with the levels of anti‐FIRΔexon2 Ab, CEA, and CA19‐9. In conclusion, anti‐FIRΔexon2 Abs detected in GC patients is a potential biomarker for monitoring a better prognosis. Hence, anti‐FIRΔexon2 Abs is a promising biomarker for indicating better overall survival of gastric cancer patients. 相似文献
997.
998.
Yasuhito Terui Shinya Rai Koji Izutsu Motoko Yamaguchi Jun Takizawa Junya Kuroda Takayuki Ishikawa Koji Kato Youko Suehiro Noriko Fukuhara Ken Ohmine Hideki Goto Kazuhito Yamamoto Nobuhiro Kanemura Yasunori Ueda Kenichi Ishizawa Kyoya Kumagai Atsuko Kawasaki Tomohisa Saito Misato Hashizume Hirohiko Shibayama 《Cancer science》2021,112(7):2845-2854
Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2, rituximab 375 mg/m2 (pola + BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Primary endpoint was complete response rate (CRR) at the end of the treatment (EOT) by positron emission tomography–computed tomography (PET-CT) using modified Lugano Response Criteria. Secondary endpoints included efficacy, safety, and pharmacokinetics. Thirty-five patients (median age 71 [range 46-86] years) were enrolled. Twenty-three (66%) patients had refractory disease, and 23 (66%) had ≥2 prior lines of therapy. At a median follow-up of 5.4 (0.7-11.9) months, patients received a median of five treatment cycles. CRR was 34.3% (95% confidence interval [CI] 19.1-52.2) at EOT. Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable). Median overall survival was not reached. No fatal adverse events (AEs) were observed. Grade 3-4 AEs were mainly hematological: anemia (37%), neutropenia (31%), white blood cell count decreased (23%), thrombocytopenia/platelet count decreased/neutrophil count decreased (20% each), and febrile neutropenia (11%). Grade 1-2 peripheral neuropathy (PN; sensory and/or motor) was reported in 14% of patients; there were no ≥grade 3 PN events. This study (JapicCTI-184048) demonstrated the efficacy and safety of pola + BR in Japanese patients with R/R DLBCL who were ineligible for ASCT. 相似文献
999.
Hanxiao Shi Atsuko Niimi Toshiyuki Takeuchi Kazuya Shiogama Yasuyoshi Mizutani Taisuke Kajino Kenichi Inada Tetsunari Hase Takahiro Hatta Hirofumi Shibata Takayuki Fukui Toyofumi Fengshi Chen-Yoshikawa Kazuki Nagano Takashi Murate Yoshiyuki Kawamoto Shuta Tomida Takashi Takahashi Motoshi Suzuki 《Cancer science》2021,112(7):2770-2780
1000.
Miyake Hideaki Sato Ryo Watanabe Kyohei Matsushita Yuto Watanabe Hiromitsu Motoyama Daisuke Ito Toshiki Sugiyama Takayuki Otsuka Atsushi 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(9):1745-1751
International Journal of Clinical Oncology - Cabazitaxel has played an important role in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC); however, several... 相似文献